Ironwood Pharmaceuticals (IRWD) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Sagimet Biosciences Series A (SGMT) over the past year, gaining 115.8% versus a gain of 3.6%. Sagimet Biosciences Series A is the larger company by market cap ($633.2 million vs $631.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | SGMT |
|---|---|---|
| Share price | $3.82 | $8.93 |
| Market cap | $631.22M | $633.21M |
| 1-day change | -1.29% | +0.11% |
| YTD return | +13.35% | +50.84% |
| 1-year return | +115.82% | +3.60% |
| 5-year return | -71.67% | — |
| P/E ratio (TTM) | 5.03 | — |
| Forward P/E | 2.55 | — |
| EPS (TTM) | $0.76 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $11.45 |
| 52-week low | $1.41 | $4.50 |
| Distance from 52-week high | -33.91% | -22.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +59.69% | +212.54% |
| Average volume | 2.01M | 1.24M |
| Shares outstanding | 165.24M | 70.34M |
| Employees | 100 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed SGMT by 112.2 percentage points over the past year.
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
IRWD vs SGMT FAQ
Which is bigger, Ironwood Pharmaceuticals or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $633.21M compared with $631.22M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, IRWD or SGMT?
IRWD returned +115.82% over the past 12 months, compared with +3.60% for SGMT (price return, excluding dividends). Past performance does not predict future results.
Are Ironwood Pharmaceuticals and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.